Schwenger Katherine Jp, Clermont-Dejean Nayima, Allard Johane P
Toronto General Hospital, University Health Network, Toronto, Canada.
Department of Medicine, University of Toronto, Toronto, Canada.
JHEP Rep. 2019 Jul 31;1(3):214-226. doi: 10.1016/j.jhepr.2019.04.004. eCollection 2019 Sep.
Recent research has suggested a role for the intestinal microbiota in the pathogenesis and potential treatment of a wide range of liver diseases. The intestinal microbiota and bacterial products may contribute to the development of liver diseases through multiple mechanisms including increased intestinal permeability, chronic systemic inflammation, production of short-chain fatty acids and changes in metabolism. This suggests a potential role for pre-, pro- and synbiotic products in the prevention or treatment of some liver diseases. In addition, there is emerging evidence on the effects of faecal microbial transplant. Herein, we discuss the relationship between the intestinal microbiota and liver diseases, as well as reviewing intestinal microbiota-based treatment options that are currently being investigated.
最近的研究表明,肠道微生物群在多种肝脏疾病的发病机制及潜在治疗中发挥作用。肠道微生物群及其细菌产物可能通过多种机制促进肝脏疾病的发展,包括肠道通透性增加、慢性全身性炎症、短链脂肪酸的产生以及代谢变化。这表明益生元、益生菌和合生元产品在某些肝脏疾病的预防或治疗中具有潜在作用。此外,关于粪便微生物移植的效果也有新的证据。在此,我们讨论肠道微生物群与肝脏疾病之间的关系,并综述目前正在研究的基于肠道微生物群的治疗选择。